Literature DB >> 10394411

Cancer epidemiology and patient recruitment for hadron therapy.

H Engels1, A Wambersie.   

Abstract

Patient recruitment is an important issue in the feasibility study of a hadron therapy programme such as Med-AUSTRON. Data on cancer incidence in Europe, Austria, and neighbouring countries are reviewed for the most frequent tumors suitable for charged particle therapy. From these data, the numbers of potential patients suitable for MED-AUSTRON are derived for each tumor site by applying the coefficients proposed in the EULIMA-1992 feasibility study. Whatever the assumptions made, a sufficient and adequate recruitment for MED-AUSTRON can be expected. However, an appropriate referring system has to be established within Austria and also in the neighbouring countries.

Entities:  

Mesh:

Year:  1999        PMID: 10394411     DOI: 10.1007/bf03038902

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  2 in total

1.  Potential clinical gain of proton (and heavy ion) beams for brain tumors in children.

Authors:  A Wambersie; V Gregroire; J M Brucher
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

2.  Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990.

Authors:  R J Black; F Bray; J Ferlay; D M Parkin
Journal:  Eur J Cancer       Date:  1997-06       Impact factor: 9.162

  2 in total
  2 in total

1.  Epidemiological study of the incidence of cancers eligible for proton or carbon ions therapy: methodology and results of recruitment estimation.

Authors:  Stéphanie Patin; Pascal Pommier; Hu Yi; Marie Hélène Baron; Jacques Balosso
Journal:  J Cancer Epidemiol       Date:  2013-06-20

2.  A Preliminary Study on the Estimation of the Number of Cancer Patients Eligible for Hadron Therapy in Iran and Fars Province.

Authors:  Mohammad Amin Hosseini; Mohammad Mohamadianpanah; Mohammad Zare-Bandeamiri; Mohammad Amin Mosleh-Shirazi
Journal:  Iran J Med Sci       Date:  2018-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.